HHS Withdraws 340B Contract Pharmacy Advisory Opinion, Says May 17 Demand Letters Are Unaffected
The U.S. Health and Human Services Department (HHS) yesterday withdrew its December 2020 legal advisory opinion (AO) that the 340B statute unambiguously requires drug manufacturers to offer 340B pricing on their products when covered entities use contract pharmacies or other distribution methods.
The U.S. Health and Human Services Department (HHS) yesterday withdrew its December 2020 legal advisory opinion on 340B contract pharmacy. Also, HHS Secretary Xavier Becerra appointed members to the 340B program administrative dispute resolution (ADR) board.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, take advantage of a 20% discount through June 30: 20% off our regular subscription rates. Subscribe now using coupon code 340Bintelligence at checkout.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
